Sanaria Inc.

18 articles about Sanaria Inc.

• Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio

  6/19/2019

  According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.

• The Government of Equatorial Guinea, US Energy Companies, and Sanaria Sign Agreements to Extend Support for Clinical Development of PfSPZ Vaccine for Malaria and a Pathway Towards Malaria Elimination on Bioko Island

  4/10/2019

  Sanaria Inc. and the Government of Equatorial Guinea last week signed an agreement that continues their joint commitment to develop Sanaria® PfSPZ Vaccine as a tool for malaria elimination.

• 

  Promising Early-Stage Results for Novel Malaria Therapeutics

  10/3/2018

  Two antimalarial strategies have been published from Imperial College London in the past month: new compounds that prevent the malaria parasite from infecting mosquitoes and gene-edited mosquitoes that cannot reproduce, leading to population destruction.

• SiO2 Medical Products And Sanaria Inc. Sign Agreement For Cryogenic Vials For PfSPZ Vaccine To Prevent Malaria

  8/1/2017

• CryoPort Expands Agreement With Sanaria Inc. To Support Grant Awards With NIH And U.S. Army

  6/7/2017

• Sanaria Inc.'s PfSPZ-CVac Vaccine Achieves High Level Protection Against Malaria In Clinical Trial

  2/16/2017

• Sanaria Inc. Release: Pharma's PfSPZ Vaccine Provides High Level Defense Against Malaria In U.S. Navy And Army Clinical Investigation

  1/12/2017

• Sanaria Inc. PfSPZ Vaccine Against Malaria Receives D&A Pharma Fast Track Designation

  9/22/2016

• Sanaria Inc.'s Malaria Vaccine Yields Unprecedented Protection In Clinical Trial

  5/9/2016

• CryoPort, Inc. And Sanaria Inc. Expand Logistics Partnership Supporting Malaria Vaccines

  2/23/2015

• Sanaria Inc.'s Malaria Vaccine Impresses in Phase 1 Trial

  8/9/2013

• Malaria Vaccine Developer Sanaria Inc.. and the Institute for Bioscience and Biotechnology Research of the University of Maryland College Park Awarded Collaborative, US $3M National Institutes of Health (NIH) Phase II Small Business Innovation Research Gr

  6/14/2012

• Malaria Parasite and Mosquito Products and Assay Services Available for Sale by Sanaria Inc.

  6/30/2011

• Sanaria Inc. Receives Multi-Year U.S. NIH Phase II Small Business Innovation Research Grant to Develop a Genetically Attenuated Whole Parasite Malaria Vaccine

  2/23/2010

• Sanaria Inc. Release: Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin

  4/23/2009

• Malaria Vaccine Plant Sanaria Inc. Takes a Gamble

  10/29/2007

• Biotech Company Sanaria Inc. To Open New Malaria Vaccine Plant

  10/25/2007

• Sanaria Inc. Receives Multi-Year $3.47 Million U.S. FDA Phase I And Phase II Small Business Innovation Research Grants To Enhance Development Of Its Malaria Vaccine

  1/29/2007